We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Low Cost, Saliva-Based COVID-19 Test Inspired by Glucose Test Strips for Diabetes Detects SARS-CoV-2 in 15 Minutes

By LabMedica International staff writers
Posted on 17 Jun 2021
Researchers are developing a rapid, low cost and mass manufacturable saliva-based biosensor test for COVID-19 inspired by the glucose test strips used to check blood sugar levels in people with diabetes.

The team from the University of Strathclyde (Glasgow, Scotland) claims that the test could eventually be mass manufactured for as little as 20 pence per test. More...
It is designed for rapid in the field use, similar to a lateral flow test, to allow people in community settings to determine their COVID-19 status.

When a person is self-testing, they would put saliva directly onto the test strip where the measurement is run by the instrument and the result produced on a display, avoiding the discomfort associated with nasopharyngeal swabs. Compared to other diagnostic tests, glucose blood tests can already be manufactured at scale, with test strips and readers CE marked with regulatory approval for use in the management of diabetes. This means the route to producing a COVID-19 test based on the technology can be much quicker.

The team of researchers has applied a special chemical treatment to the sensor surface to produce the test, which uses the ACE2 enzyme - the receptor that coronavirus uses to bind on to cells - meaning clinically relevant detection levels of the virus can be achieved. The experimental sensor was initially tested with inactivated virus samples at different concentrations, ranging from low to high, alongside negative samples from a commercially available molecular diagnostics standards kit. Hospital laboratory tests were then carried out on real patient samples and most recent set of experiments showed detection was possible in 15 minutes.

The team has patented the experimental technology and will use clinical samples to translate this proof of concept work into a working product. The aim is to develop the test into a CE marked commercial product for real world use. The first version of the test for emergency use is expected to be ready in 12 months and a fully CE marked test is likely to be on the market in 18-24 months.

“The test would provide a scalable route to sensitive, specific, rapid and low-cost testing for COVID-19, but in addition could serve as a low cost tool to rapidly diagnose other respiratory viruses and determine whether someone has COVID-19, flu or rhinovirus,” said lead investigator, Dr. Damion Corrigan from the department of Biomedical Engineering at Strathclyde. “This means it could enable screening of workers, at very low cost, for example in their place of work, identifying and isolating those with the disease and enabling those recovered to go back to work. Initially, we will demonstrate this with COVID-19 and then commercialize the test so that we can work on using the underlying patent to produce new sensor technologies for other respiratory viruses and infectious diseases.”

Related Links:
The University of Strathclyde


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.